A method of preventing weakness in a patient with Parkinson's disease or of improving or restoring muscle strength of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said muscle strength, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where R] is one of an N-acyl group, a substituted or unsubstiruted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
Syringes with detachable needles (like Luer Lock syringes) have much higher dead space, leading to wasted product and inaccurate dosing
In: 2015
When evaluating Canadian suppliers, look for Certificate of Analysis (COA) documentation showing purity of 95% or higher, along with heavy metal and endotoxin testing results
This elimination of senescent cells occurred selectively, i.e
For a 100 mg target dose at 100 mg/mL: Volume to Draw = Desired DoseConcentration = 100 mg100 mg/mL = 1.0 mL Convert to syringe units
